within Pharmacolibrary.Drugs.ATC.H;

model H01CC01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0125,
    k12             = 2.6,
    k21             = 2.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H01CC01</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ganirelix is a synthetic decapeptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. It suppresses the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by competitively binding to GnRH receptors in the pituitary gland. Ganirelix is primarily used in assisted reproductive technology (ART) to prevent premature luteinizing hormone surges during controlled ovarian hyperstimulation. It is approved and currently used for this purpose.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult women undergoing controlled ovarian stimulation.</p><h4>References</h4><ol><li><p>Gillies, PS, et al., &amp; Perry, CM (2000). Ganirelix. <i>Drugs</i> 59(1) 107–113. DOI:<a href=\"https://doi.org/10.2165/00003495-200059010-00007\">10.2165/00003495-200059010-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10718102/\">https://pubmed.ncbi.nlm.nih.gov/10718102</a></p></li><li><p>Oberyé, JJ, et al., &amp; Timmer, CJ (1999). Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. <i>Fertility and sterility</i> 72(6) 1001–1005. DOI:<a href=\"https://doi.org/10.1016/s0015-0282(99)00413-6\">10.1016/s0015-0282(99)00413-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10593371/\">https://pubmed.ncbi.nlm.nih.gov/10593371</a></p></li><li><p>Oberyé, JJ, et al., &amp; Timmer, CJ (1999). Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. <i>Fertility and sterility</i> 72(6) 1006–1012. DOI:<a href=\"https://doi.org/10.1016/s0015-0282(99)00414-8\">10.1016/s0015-0282(99)00414-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10593372/\">https://pubmed.ncbi.nlm.nih.gov/10593372</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H01CC01;
